552	BI_99179
BI 99179 &&&&& Introduction &&&&& &&&&& &&&&& '''BI 99179''' is a selective small molecule inhibitor suitable for the ''in vivo'' validation of type 1 fatty acid synthase (FAS) as a therapeutic target for lipid metabolism-related disorders (lipid metabolism disorder) which has been discovered by Boehringer Ingelheim. &&&&& 3D model of BI 99179 &&&&& &&&&& Summary &&&&& BI 99179 is characterized by its high potency, high selectivity, and significant exposure (both peripheral and central) upon oral administration in rats. &&&&& &&&&& Target information &&&&& Mammalian type I FAS is a multi-enzyme protein that catalyzes fatty acid synthesis. It mediates key roles in neoplastic lipogenesis and is highly expressed in lipogenic tissues. While most tissues, except liver and adipose tissue, have low levels of FAS expression and activity, FAS is over-expressed in many cancers. Accumulating evidence suggests that it is a metabolic oncogene with an important role in tumor growth and survival, thus making it an attractive target for cancer therapy. In addition to its role in oncology, FAS inhibition could also represent an attractive therapeutic target in obesity; both systemic and intracerebroventricular treatment of mice with FAS inhibitors led to inhibition of feeding and dramatic weight loss. Moreover, inhibitors of FAS have been reported to reduce the production of sebum in sebocytes; therefore, topical FAS inhibition could be a potential anti-acne approach. &&&&& &&&&& FAS consists of two identical subunits, each comprising an acyl carrier protein (ACP) domain and six different catalytic domains. BI 99179 is likely to bind to the ketoacyl reductase (KR) domain (evidence: Boehringer Ingelheim enzymatic data and analogy to the published co-crystal structure of the human KR domain with GSK2194069). &&&&& &&&&& ''In vitro'' activity &&&&& BI 99179 inhibits the FAS enzyme isolated from HeLa cells with a half maximal inhibitory concentration (IC50) of 79 nM. &&&&& &&&&& &&&&& &&&&& '''''In Vitro'' Activity''' &&&&& &&&&& &&&&& &&&&& Probe name &&&&& &&&&& BI 99179 &&&&& &&&&& &&&&& &&&&& Inhibition of FASN* (IC50) nM &&&&& &&&&& 79 &&&&& &&&&& &&&&& &&&&& Inhibition of 14Cacetate incorporation§ mouse N-42 cells (IC50) nM &&&&& &&&&& 570 &&&&& &&&&& &&&&& &&&&& Inhibition of 14Cacetate incorporation§ hum. H1975 cells (IC50) nM &&&&& &&&&& 180 &&&&& &&&&& &&&&& &&&&& Cytotoxicity (LDH release from U937 cells) (IC50) nM &&&&& &&&&& >30000 &&&&& &&&&& &&&&& &&&&& *Human FAS enzyme isolated from HeLa cells. &&&&& &&&&& §Cells incubated with compound for 1 hour, 14C-acetate in Krebs–Ringer &&&&& &&&&& buffer incubation for 4 hours, methanol:CHCl3 1:1 extraction, measurement in ß-counter. &&&&& &&&&& FASN, fatty acid synthase; LDH, lactate dehydrogenase. &&&&& &&&&& &&&&& &&&&& &&&&& &&&&& '''''In Vitro'' DMPK and CMC''' &&&&& &&&&& &&&&& &&&&& Probe name &&&&& &&&&& BI 99179 &&&&& &&&&& &&&&& &&&&& Aqueous solubility @ pH 7 µg/ml &&&&& &&&&& >39 &&&&& &&&&& &&&&& &&&&& CACO permeability @pH7.4 *10-6 cm/s &&&&& &&&&& 94 &&&&& &&&&& &&&&& &&&&& CACO efflux ratio &&&&& &&&&& 0.9 &&&&& &&&&& &&&&& &&&&& Microsomal stability – rat, human % QH &&&&& &&&&& <27 &&&&& &&&&& &&&&& &&&&& Plasma protein binding rat % QH &&&&& &&&&& 97.6 &&&&& &&&&& &&&&& &&&&& ''In vivo'' DMPK &&&&& &&&&& &&&&& &&&&& '''''In Vivo'' DMPK Parameters''' &&&&& &&&&& &&&&& &&&&& Probe name &&&&& &&&&& BI 99179 &&&&& &&&&& &&&&& &&&&& t½ (h) &&&&& &&&&& 3.0 &&&&& &&&&& &&&&& &&&&& tmax (h) &&&&& &&&&& 0.5 &&&&& &&&&& &&&&& &&&&& Cmax (nM) &&&&& &&&&& 2110 &&&&& &&&&& &&&&& &&&&& AUC0–inf (nMh) &&&&& &&&&& 9350 &&&&& &&&&& &&&&& &&&&& F (%) &&&&& &&&&& 46 &&&&& &&&&& &&&&& &&&&& CL (ml/min/kg) &&&&& &&&&& 8.2 &&&&& &&&&& &&&&& &&&&& Vss (l/kg) &&&&& &&&&& 1.6 &&&&& &&&&& &&&&& &&&&& Cbrain,2h (nM) &&&&& &&&&& 1300 &&&&& &&&&& &&&&& &&&&& CCSF,2h (nM) &&&&& &&&&& 50 &&&&& &&&&& &&&&& &&&&& Pharmacokinetic parameters of BI 99179 in male Wistar Hannover rats. &&&&& &&&&& Fasted upon oral application of 4 mg/kg. &&&&& &&&&& &&&&& &&&&& ''In vivo'' pharmacology &&&&& BI 99179 showed acute efficacy in rat models. &&&&& &&&&& * Increased hypothalamic Malonyl-CoA concentrations (10 or 100 mg/kg; 2 hours/24 hours post dose (p.d.) &&&&& * Decreased cumulative food intake 100 mg/kg; 24 hours p.d. &&&&& &&&&& Selectivity &&&&& A screen covering 30 targets was reported: <20% inhibition at 10 µM for all targets. &&&&& &&&&& References &&&&& &&&&& &&&&& Further reading &&&&& * Alexandra D'Arcangelis, John Bajor, Kimberly Campbell, Helen Knaggs. U.S. Patent 53631, '''2005'''. &&&&& * &&&&& &&&&& &&&&& &&&&& &&&&& 